cygnus- die chance der zukunft? - 500 Beiträge pro Seite

[anBvsnGlaubender]

Ich beobachte seit ca. 1 Jahr die amerikanische Aktie Cygnus und bin aufgrund der Unternehmenszahlen und den zukünfzigen Aussichten überzeugt, dass die Aktie dieses Jahr einer der Outperformer wird.
Deshalb habe ich die aktie vor 6 wochen gekauft und der anstieg bis jetzt war erst der anfang.

Meine oma ist auch diabetiker und als ich ihr von der "glucowatch" erzählt habe, wollte sie auch so eine haben.
Da der Verkauf in europa und den usa gerade erst anläuft werden meiner ansicht nach schon die nächsten zahlen überraschend positiv ausfallen.

hier die Quarttalsbericht:


Archived News Releases


CYGNUS REPORTS FIRST QUARTER FINANCIAL RESULTS

Redwood City, CA - April 26, 2001 - Cygnus, Inc. (Nasdaq: CYGN) today reported total revenue of $5.0 million for the quarter ended March 31, 2001, compared to $1.0 million for the quarter ended March 31, 2000. Cygnus posted a net loss of $4.9 million ($0.18/share) for the quarter ended March 31, 2001, compared to a net loss of $5.1 million ($0.20/share) for the quarter ended March 31, 2000.

The quarter was highlighted by the United States Food and Drug Administration (FDA) granting Cygnus approval to market its GlucoWatch® Biographer on March 22, 2001. "Receiving FDA approval was a monumental event in Cygnus` history. We received outstanding media coverage that led to tens of thousands of people visiting our new web site (www.glucowatch.com) to learn more about the GlucoWatch Biographer," stated John C Hodgman, Chairman, Chief Executive Officer and President. The medical journal Diabetes Care published research demonstrating the effectiveness of the Biographer in detecting hypoglycemia (low blood glucose levels) in the May 2001 issue. "We believe the GlucoWatch Biographer is a unique device that can make significant contributions toward improving diabetes management. We plan to build on this momentum as we prepare to commercialize this revolutionary product in the U.S. and other countries."

Contract revenues for the quarter ended March 31, 2001 are primarily due to milestone revenue related to the FDA approval of the GlucoWatch Biographer. Contract revenues for the quarter ended March 31, 2000 consisted primarily of the amortization of a milestone payment received in 1999 associated with the GlucoWatch Biographer. Research and development costs were $6.8 million for the quarter ended March 31, 2001, compared to $3.8 million for the quarter ended March 31, 2000. This increase is primarily due to an increase in expenses incurred to develop and test high-capacity manufacturing processes. Marketing, general and administrative expenses for the quarter ended March 31, 2001 were $3.1 million, compared to $1.9 million for the quarter ended March 31, 2000. This increase is primarily due to marketing efforts to support the launch in the United Kingdom and in preparation for the U.S. pilot marketing program and this increase included expenses related to product packaging, training materials, customer service, advertising and sales materials, as well as the development and launch of Cygnus` glucowatch.com web site.

The provision for taxes relates to foreign tax withholding applicable to the milestone revenue recorded in this quarter and in the first quarter of 2000.

Cash and investments totaled $16.0 million as of March 31, 2001. In the first week of April 2001, Cygnus collected the $4.5 million (net of tax) receivable for the contract revenue recognized in the first quarter 2001.

Cygnus also announced today that it has begun its U.S. pilot marketing program. "Fifteen geographically dispersed sites have been identified and site training and recruiting of patients is underway," noted Craig W. Carlson, Chief Operating Officer and Chief Financial Officer of Cygnus, Inc. "In addition, our controlled launch plan in the United Kingdom, which includes three stages, is right on track. During the first quarter, we successfully completed the first stage, which was to hire and train field representatives, to fine-tune logistics and customer service functions and to begin training a limited number of diabetes clinics in order to evaluate the effectiveness of our programs. The focus of the second stage, which has already begun, is to expand significantly on the number of diabetes clinics trained. The third stage, anticipated to begin in the second half of 2001, will emphasize generating awareness and sales among people with diabetes. Our experiences with health care professionals in the United Kingdom have been very positive and we look forward to expanding our launch later in 2001."

The company`s results of operations and level of revenues may vary significantly from period to period and are not necessarily indicative of expected results of operations or revenues in future periods.

Cygnus, Inc., headquartered in Redwood City, California, develops and manufactures non-invasive diagnostic medical devices, utilizing proprietary biosensor technologies to satisfy unmet medical needs cost-effectively. The company`s current efforts are focused on a frequent, automatic, and non-invasive glucose monitoring device (the GlucoWatch Biographer) and enhancements thereto.

This news release contains forward-looking statements regarding future events and the future performance of the Company that involve risks and uncertainties that may cause the Company`s actual results to differ materially. There can be no assurance that unforeseen problems will not occur in product manufacturing and commercial scale-up or marketing or product distribution of the GlucoWatch Biographer or that regulatory approval will be received for large-scale manufacturing processes. Any such occurrence could significantly delay the commercialization of the GlucoWatch Biographer system or prevent its market introduction entirely. Further, there can be no assurance that the Company will be able to enter into a commercialization alliance or alliances or that the Company will be able to outsource certain commercialization capabilities for launch without a worldwide commercialization alliance in place. There also can be no assurance that the product can be successfully manufactured in commercial quantities at a reasonable cost, be marketed successfully or achieve market acceptance. Furthermore, as the Company seeks regulatory approval for enhancements and possible manufacturing changes through the pre-market approval (PMA) supplement process, there can be no assurance that such supplements will be approved or that one or more new PMAs will not need to be filed. The Company refers you to the documents the Company files from time to time with the Securities and Exchange Commission, including the Company`s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, which contain descriptions of certain factors that could cause the Company`s actual results to differ from the Company`s current expectations and any forward-looking statements contained in this news release. "GlucoWatch" is a registered trademark of Cygnus, Inc.


Financial Table to Follow


CYGNUS, INC.

Consolidated Condensed Statements of Operations

(In thousands, except per share data)

(unaudited)


Three months ended
March 31,

2001 2000

Contract Revenues $ 5,033 $ 1,038

Costs and Expenses:
Research and development 6,755 3,829

Marketing, general and 3,147 1,908
administrative

Total costs and expenses 9.902 5,737


Loss from operations (4,869) (4,699)

Other income & (expense) 422 (316)

Loss from operations $ (4,447) $ (5,015)
before income tax

Provision for taxes (500) (100)

Net loss $ (4,947) $ (5,115)

Net loss per share, $ (0.18) $ (0.20)
basic and diluted

Shares used in computation 27,715 25,527
of net loss per share,
basic and diluted


Summary Consolidated Condensed Balance Sheet

(In thousands)

(unaudited)

March 31,
2001

Current assets $22,437

Equipment and improvements, net 6,597

Other assets 606
Total assets $ 29,640

Current liabilities 15,663

Long-term obligations 30,915

Stockholders` equity ) (16,938)
(net capital deficiency

Total liabilities and $29,640
stockholders` net
capital deficiency

www.cygn.com

würde mich sehr über eure meinungen freuen.

mfG anBvsnGlaubender

[sittin bull inv]

Im Moment wenig Bewegung.

Kann aber noch sehr gute Aktie werden.
Die ersten Verkaufszahlen werden es zeigen.